{"title": "Argentina | GSK", "author": null, "url": "https://www.gsk.com/en-gb/locations/argentina/es-arg/", "hostname": "gsk.com", "description": "GSK Argentina", "sitename": "Gsk", "date": "2023-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Con una trayectoria de m\u00e1s de 100 a\u00f1os en el pa\u00eds, contamos con 4 unidades de negocio (Medicinas Generales, Vacunas, Especialidades y Oncolog\u00eda) en donde investigamos, desarrollamos y producimos soluciones innovadoras para mejorar la calidad de vida de millones de argentinos.\nHace m\u00e1s de 20 a\u00f1os que llevamos a cabo Investigaci\u00f3n y Desarrollo (R&D) en el pa\u00eds, con excelentes resultados, que impactan en la salud y la calidad de vida de los pacientes, as\u00ed como en experiencia para los grupos de investigadores, debido a su participaci\u00f3n en estudios que se publican en los medios cient\u00edficos m\u00e1s importantes a nivel global. Durante 2021, invertimos 7 millones de d\u00f3lares en m\u00e1s de 25 estudios que involucraron la participaci\u00f3n de 80 centros de investigaci\u00f3n en todo el pa\u00eds.\nDesde 2011, mantenemos un acuerdo de colaboraci\u00f3n y cofinanciamiento p\u00fablico-privado para apoyar la investigaci\u00f3n cient\u00edfica b\u00e1sica, llamado Trust in Science. Una de las principales premisas del programa es la transparencia y el respeto por la propiedad intelectual, que pertenece al investigador y/o instituci\u00f3n que realiza el descubrimiento. La inversi\u00f3n realizada hasta la fecha es de $6.3 millones de d\u00f3lares y ha apoyado m\u00e1s de 30 proyectos de investigaci\u00f3n sobre enfermedades de alta prioridad social, de las que han participado 110 investigadores de diferentes centros de referencia a nivel nacional.\nEn lo que respecta a nuestra \u00e1rea de Investigaci\u00f3n y Desarrollo, en 2022 se encuentran 25 estudios activos y 10 estudios planeados en m\u00e1s de 100 centros de investigaci\u00f3n en diferentes \u00e1reas terap\u00e9uticas.\nEn el 2022 inauguramos nuevas oficinas y laboratorio de control de calidad en la Ciudad de Buenos Aires. Nuestras modernas oficinas se encuentran ubicadas en el barrio de N\u00fa\u00f1ez, cuentan con 2400 mts2 y all\u00ed trabajan 200 empleados. Fueron dise\u00f1adas con el concepto de modern employer, con espacios de colaboraci\u00f3n, estaciones de concentraci\u00f3n y diversas salas de reuniones, entre otros aspectos.\nNuestro nuevo laboratorio de control de calidad cuenta con 1500 mts2 y m\u00e1s de 50 equipos de alta tecnolog\u00eda preparados para vacunas, HIV, Oncolog\u00eda y Rx.\nM\u00e1s de 330 colaboradores son parte de nuestro equipo y hemos sido reconocidos 3 veces en el Top 10 del ranking Great Place to Work en Argentina.\nCarreras\n\u00bfQuer\u00e9s trabajar con nosotros?\nDirecci\u00f3n de contacto\nCentro Empresarial Libertador\nLibertador 7208 CP: 1429\nCiudad Aut\u00f3noma de Buenos Aires\nTel:\n[+54 11 5218 8900](tel:+54 11 5218 8900)\nPara consultas generales\nReporte de evento adverso\nEn GSK tomamos la seguridad de nuestros pacientes y consumidores muy en serio. Por esta raz\u00f3n, es vital para nosotros monitorear continuamente la seguridad de nuestros productos. Al escuchar sus experiencias y las de otros como usted somos capaces de ofrecer el mejor asesoramiento posible a los que utilizan nuestros productos.\n\u00bfC\u00f3mo informar de un posible efecto secundario?\nPor consultas o reclamos de producto farmac\u00e9utico y/o reporte de eventos adversos comun\u00edquese al\n[0800-220-4752](tel:0800-220-4752) de Lunes a Viernes de 09:00 a 20:00.\nEn caso de querer reportar eventos adversos por mail, puede enviar los detalles del caso a\n[ww.gskaereportingamericas@gsk.com](mailto:ww.gskaereportingamericas@gsk.com)\nPara ayudarnos a procesar su informaci\u00f3n de forma r\u00e1pida y eficaz, por favor recuerde que debe brindar toda la informaci\u00f3n relevante posible. Como m\u00ednimo tendr\u00e1 que proporcionar lo siguiente:\n- Las iniciales de la persona que experiment\u00f3 el posible efecto adverso y/u otros identificadores, como la fecha de nacimiento.\n- La informaci\u00f3n de contacto de la persona que est\u00e1 reportando el problema.\n- Descripci\u00f3n del posible efecto adverso (los signos y/o s\u00edntomas experimentados, fecha de comienzo del posible efecto adverso y la evoluci\u00f3n de \u00e9ste).\n- El nombre del producto de GSK involucrado.\n[Back to top](#)\nPrensa\nPiera Basile\nGerente de Comunicaciones y Asuntos Gubernamentales de GSK Argentina\nEmail:\n[piera.m.basile@gsk.com](mailto:piera.m.basile@gsk.com) [Back to top](#)\nProfesionales de la salud\n\u00bfSos profesional de la salud y necesitas informaci\u00f3n de nuestros productos? Ingres\u00e1 a\n[GSKPro](https://gskpro.com/es-ar/)\nC\u00f3digo de Conducta de GSK\n\u00bfQuer\u00e9s conocer m\u00e1s sobre nuestros Valores y Expectativas? Pod\u00e9s consultar nuestro C\u00f3digo de Conducta que condensa los lineamientos de nuestro accionar basado en: Respeto, Integridad, Transparencia y poner en el Centro a nuestros Pacientes y Clientes.\n[Lee nuestro C\u00f3digo de Conducta](/media/9648/nuestro-c\u00f3digo.pdf) (PDF-311KB)", "language": null, "image": "https://www.gsk.com/assets/img/GSK_Logo_Full_Colour_RGB.png?mode=pad&width=350&height=157", "pagetype": "website", "links": ["#main-content", "#header-search", "/en-gb/locations/", "https://www.gskpro.com", "/en-gb/contact-us/", "/en-gb/search/", "#", "", "/en-gb/", "/en-gb/behind-the-science-magazine/", "", "/en-gb/behind-the-science-magazine/", "/en-gb/behind-the-science-magazine/", "/en-gb/company/", "", "/en-gb/company/", "/en-gb/company/", "/en-gb/company/purpose-strategy-and-culture/", "/en-gb/company/outstanding-people/", "", "/en-gb/company/outstanding-people/", "/en-gb/company/outstanding-people/working-together/", "/en-gb/company/outstanding-people/my-gsk-story/", "/en-gb/company/outstanding-people/innovating-together-2022/", "/en-gb/company/outstanding-people/innovating-together-2021/", "/en-gb/company/gsk-at-a-glance/", "/en-gb/company/history-and-heritage/", "/en-gb/company/board-of-directors-and-leadership-team/", "/en-gb/company/board-information/", "/en-gb/company/governance/", "", "/en-gb/company/governance/", "/en-gb/company/governance/committees/", "/en-gb/company/governance/shareholders/", "/en-gb/company/governance/sarbanes-oxley-act-2002/", "/en-gb/company/governance/compliance/", "/en-gb/company/policy-positions/", "/en-gb/company/codes-standards-and-reports/", "/en-gb/company/purpose-strategy-and-culture/", "/en-gb/company/outstanding-people/", "/en-gb/innovation/", "", "/en-gb/innovation/", "/en-gb/innovation/", "/en-gb/innovation/research-and-development-approach/", "/en-gb/innovation/pipeline/", "/en-gb/innovation/therapeutic-areas/", "", "/en-gb/innovation/therapeutic-areas/", "/en-gb/innovation/therapeutic-areas/infectious-diseases/", "/en-gb/innovation/therapeutic-areas/hiv/", "/en-gb/innovation/therapeutic-areas/respiratoryimmunology/", "/en-gb/innovation/therapeutic-areas/oncology/", "/en-gb/innovation/therapeutic-areas/opportunity-driven/", "/en-gb/innovation/technologies/", "/en-gb/innovation/trials/", "", "/en-gb/innovation/trials/", "/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/", "/en-gb/innovation/trials/data-transparency/", "/en-gb/innovation/trials/diversity-in-clinical-trials/", "/en-gb/innovation/partnerships/", "", "/en-gb/innovation/partnerships/", "/en-gb/innovation/partnerships/supported-studies/", "/en-gb/innovation/rd-locations/", "/en-gb/behind-the-science-magazine/", "/en-gb/innovation/partnerships/", "/en-gb/products/", "", "/en-gb/products/", "/en-gb/products/", "/en-gb/products/our-product-areas/", "/en-gb/products/products-a-z/", "/en-gb/innovation/", "https://gskpro.com", "/en-gb/responsibility/", "", "/en-gb/responsibility/", "/en-gb/responsibility/", "/en-gb/responsibility/access/", "/en-gb/responsibility/global-health-and-health-security/", "", "/en-gb/responsibility/global-health-and-health-security/", "/en-gb/responsibility/global-health-and-health-security/global-health/", "/en-gb/responsibility/global-health-and-health-security/health-security/", "/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/", "/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/", "/en-gb/responsibility/environment/", "", "/en-gb/responsibility/environment/", "/en-gb/responsibility/environment/climate/", "/en-gb/responsibility/environment/water/", "/en-gb/responsibility/environment/materials-and-waste/", "/en-gb/responsibility/environment/biodiversity/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "/en-gb/responsibility/ethical-standards/", "", "/en-gb/responsibility/ethical-standards/", "/en-gb/responsibility/ethical-standards/working-with-third-parties/", "/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/", "/en-gb/responsibility/ethical-standards/human-rights/", "/en-gb/responsibility/ethical-standards/use-of-animals/", "/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/", "/en-gb/responsibility/product-governance/", "/en-gb/responsibility/charitable-investments/", "/en-gb/responsibility/esg-resources/", "", "/en-gb/responsibility/esg-resources/", "/en-gb/responsibility/esg-resources/esg-reports-archive/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "/en-gb/company/policy-positions/", "/en-gb/investors/", "", "/en-gb/investors/", "/en-gb/investors/", "/en-gb/investors/why-invest-in-gsk/", "/en-gb/investors/quarterly-results/", "/en-gb/investors/financial-reports/", "", "/en-gb/investors/financial-reports/", "/en-gb/investors/financial-reports/annual-report-2022/", "/en-gb/investors/financial-reports/corporate-reports-archive/", "/en-gb/investors/environmental-social-and-governance/", "/en-gb/investors/speeches-and-presentations/", "/en-gb/investors/events-calendar/", "/en-gb/investors/dividend-and-share-price/", "", "/en-gb/investors/dividend-and-share-price/", "/en-gb/investors/dividend-and-share-price/gsk-share-price/", "/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/", "/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/", "/en-gb/investors/dividend-and-share-price/dividend-calendar/", "/en-gb/investors/analyst-consensus/", "/en-gb/investors/shareholder-information/", "", "/en-gb/investors/shareholder-information/", "/en-gb/investors/shareholder-information/manage-your-shares/", "/en-gb/investors/shareholder-information/annual-general-meeting/", "/en-gb/investors/shareholder-information/general-meeting/", "/en-gb/investors/shareholder-information/annual-governance-meeting/", "/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/", "/en-gb/investors/shareholder-information/adr-programme/", "/en-gb/investors/shareholder-information/asset-reunification-prosearch/", "/en-gb/investors/shareholder-information/share-scam-alert/", "/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/", "/en-gb/investors/shareholder-information/shareholder-faqs/", "/en-gb/investors/stock-exchange-announcements/", "", "/en-gb/investors/stock-exchange-announcements/", "/en-gb/investors/stock-exchange-announcements/london-rns/", "/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/", "/en-gb/investors/stock-exchange-announcements/new-york-sec/", "/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/", "/en-gb/investors/corporate-actions/", "", "/en-gb/investors/corporate-actions/", "/en-gb/investors/corporate-actions/consumer-healthcare-demerger/", "/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/", "/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/", "/en-gb/investors/debt-investors/", "/en-gb/investors/investor-contacts/", "/en-gb/media/press-releases/", "/en-gb/innovation/pipeline/", "/en-gb/media/", "", "/en-gb/media/", "/en-gb/media/", "/en-gb/media/press-releases/", "/en-gb/media/media-contacts/", "/en-gb/media/conferences/", "/en-gb/media/media-library/", "/en-gb/media/our-response-to-the-situation-in-ukraine/", "/en-gb/media/our-response-to-covid-19/", "/en-gb/media/social-media/", "/en-gb/media/rss-feeds/", "/en-gb/behind-the-science-magazine/", "/en-gb/media/conferences/", "/en-gb/careers/", "", "/en-gb/careers/", "/en-gb/careers/", "/en-gb/careers/search-jobs/", "/en-gb/careers/featured-careers/", "", "/en-gb/careers/featured-careers/", "/en-gb/careers/featured-careers/a-career-in-data/", "/en-gb/careers/life-at-gsk/", "", "/en-gb/careers/life-at-gsk/", "/en-gb/careers/life-at-gsk/whats-your-angle/", "/en-gb/careers/experienced-professionals/", "", "/en-gb/careers/experienced-professionals/", "/en-gb/careers/experienced-professionals/business-operations/", "/en-gb/careers/experienced-professionals/engineering/", "/en-gb/careers/experienced-professionals/manufacturing-and-supply/", "/en-gb/careers/experienced-professionals/marketing-and-sales/", "/en-gb/careers/experienced-professionals/research-and-development/", "", "/en-gb/careers/experienced-professionals/research-and-development/", "/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/", "/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/", "/en-gb/careers/experienced-professionals/technology/", "/en-gb/careers/early-talent/", "", "/en-gb/careers/early-talent/", "/en-gb/careers/early-talent/kickstart-your-career/", "/en-gb/careers/early-talent/apprentice-programmes/", "/en-gb/careers/early-talent/work-experience-placements-and-internships/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/", "", "/en-gb/careers/early-talent/future-leaders-graduate-programme/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/business-operations/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/engineering/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/manufacturing-operations-quality-supply-chain/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/marketing-and-sales/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/research-and-development/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/technology/", "/en-gb/careers/early-talent/post-graduate-opportunities/", "/en-gb/careers/our-global-and-regional-hubs/", "/en-gb/careers/how-we-hire/", "", "/en-gb/careers/how-we-hire/", "/en-gb/careers/how-we-hire/frequently-asked-questions/", "/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/", "/en-gb/company/outstanding-people/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "https://www.gskpro.com", "/en-gb/contact-us/", "/en-gb/", "/en-gb/locations/", "/en-gb/locations/argentina/", null, "/en-gb/locations/argentina/", "https://jobs.gsk.com/en-gb/jobs?location=Argentina&amp;stretch=10&amp;stretchUnit=KILOMETERS&amp;page=1&amp;woe=12", "tel:+54 11 5218 8900", "#", "tel:+54 11 5218 8900", "#", "tel:0800-220-4752", "mailto:ww.gskaereportingamericas@gsk.com", "#", "mailto:piera.m.basile@gsk.com", "#", "https://gskpro.com/es-ar/", "/media/9648/nuestro-c\u00f3digo.pdf", "#", "/", "/en-gb/locations/", "/media/9966/modern-slavery-act-statement-2022.pdf", "/en-gb/locations/", "/en-gb/media/social-media/", "https://www.gskpro.com", "https://www.gsk-studyregister.com/en/", "https://supplier.gsk.com", "https://viivhealthcare.com/", "/en-gb/behind-the-science-magazine/", "/en-gb/company/", "/en-gb/innovation/", "/en-gb/products/", "/en-gb/responsibility/", "/en-gb/investors/", "/en-gb/media/", "/en-gb/careers/", "/en-gb/innovation/partnerships/", "/en-gb/contact-us/report-a-possible-side-effect/", "https://gsk.i-sight.com/landing-page/", "https://www.facebook.com/GSK", "http://twitter.com/GSK", "http://www.youtube.com/GSK", "http://www.linkedin.com/company/glaxosmithkline", "https://www.instagram.com/gsk/", "/en-gb/media/rss-feeds/", "/en-gb/accessibility/", "/en-gb/terms-of-use/", "/en-gb/cookie-policy/", "https://privacy.gsk.com/en-gb/privacy-notice/general", "/en-gb/sitemap/", null, "#"]}